#United States #Jersey City #Mitsubishi Tanabe #ALS Treatment #RADICAVA ORS

Mitsubishi Tanabe Pharma Celebrates RADICAVA ORS® Anniversary

Mitsubishi Tanabe Pharma America, Inc. (MTPA) proudly commemorates the three-year anniversary of the launch of RADICAVA ORS® (edaravone) in the United States. Since its introduction in June 2022, this innovative oral formulation has provided over 13,500 patients living with amyotrophic lateral sclerosis (ALS) with an effective treatment option. This remarkable achievement highlights MTPA's commitment to improving the lives of those affected by this devastating condition.

A Breakthrough in ALS Treatment

Approved by the U.S. Food and Drug Administration (FDA) in May 2022, RADICAVA ORS offers the same efficacy as its intravenous counterpart, RADICAVA® (edaravone). Clinical trials have demonstrated that treatment with RADICAVA significantly slowed the decline in physical function in ALS patients, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). The results showed a 33% reduction in functional decline compared to placebo over a 24-week period, underscoring the drug's potential to enhance the quality of life for individuals battling ALS.

Growing Adoption and Data Presentation

To date, around 1,378 healthcare providers across the U.S. have prescribed RADICAVA ORS. Remarkably, 82% of patients who began treatment within the initial 20 months have continued for three months or longer, indicating the treatment's acceptance and the positive outcomes patients are experiencing. MTPA has further demonstrated its commitment to ALS awareness and education by presenting data on RADICAVA ORS at ten medical congresses globally in the past year. Notable presentations included discussions at the 2024 European Network to Cure ALS (ENCALS) Meeting in Stockholm, Sweden, and multiple sessions at the 23rd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting.

Administration and Patient Support

The administration of RADICAVA ORS involves an initial treatment cycle where patients take the medication daily for 14 consecutive days, followed by a non-treatment period of 14 days. Subsequent treatment cycles involve daily dosing for 10 out of 14 days, followed by another 14-day break. Patients are encouraged to use the provided syringe to measure their doses accurately and are instructed to store the medication at room temperature while protecting it from light.

MTPA is dedicated to supporting patients and their caregivers through initiatives like the JourneyMate Support Program™. This program offers valuable educational resources and personalized assistance for those navigating their ALS journey. Additionally, the Share Your Story program provides a platform for individuals with ALS to share their experiences, fostering a sense of community and understanding among those affected.

Ongoing Commitment to ALS Research

Mitsubishi Tanabe Pharma has been at the forefront of ALS research since 2001, focusing on innovative treatment options for this challenging disease. The company's dedication led to the initial approval of edaravone for ALS treatment in Japan in 2015, which has since expanded to various countries, including the U.S., Canada, and Brazil. The recent FDA designation of RADICAVA ORS as an Orphan Drug further underscores its significance in providing a treatment option that simplifies administration by eliminating the burdens associated with intravenous therapy.

As MTPA reflects on these three years of significant progress, it underscores its commitment to advancing research and fostering collaboration to support those living with ALS. For more information about RADICAVA ORS, visit MTPA.com/Media or RADICAVA.com/journeymate, where resources and support options are available for patients and their families.

Conclusion

The celebration of RADICAVA ORS's three-year anniversary marks not just a milestone for Mitsubishi Tanabe Pharma but a beacon of hope for many affected by ALS. The journey continues as MTPA remains focused on enhancing patient care and contributing to advancements in ALS treatment through continuous research and community support.